Nodify Lung™ consists of two blood-based proteomic tests (the Nodify CDT™ & Nodify XL2® tests) to help physicians reclassify risk of cancer and aid in stratifying patients into distinct nodule management pathways: intervention or surveillance.
Helps identify patients who may benefit from timely intervention with results in one day.
LEARN MORE ABOUT THE NODIFY CDT TEST
Helps identify patients who may benefit from computed tomography (CT) surveillance with results in one week.
Nodify Lung testing is intended for patients with incidental lung nodules:
The Nodify Lung Blood Specimen Collection Kit is used for both the Nodify CDT and the Nodify XL2 proteomic tests.
DOWNLOAD OUR INFORMATIONAL BROCHURE
ORDER NODIFY LUNG TESTING
CONTACT OUR TEAM
* According to the ACCP guidelines, patients with a Very Low risk of malignancy should be considered for CT surveillance and patients with a High risk should receive a stage evaluation and appropriate intervention.
A leading data-driven diagnostic solutions company helping answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies, with a primary focus in lung disease.
CORPORATE HEADQUARTERS
2970 Wilderness Place, Suite 100
Boulder, CO 80301
Phone (866) 432-5930
Fax (866) 432-3338
© Copyright 2020 Biodesix.
All Rights Reserved.